ArticleERJ open research2025
Characteristics and real-world health clinical outcomes of uncontrolled COPD patients: population-based study in France.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-Analysis of Immunogenicity and Safety of the Influenza Vaccine in COPD Patients, and Its Relevance with Real-World Effectiveness.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials.American journal of respiratory and critical care medicine · 2026Trial
- Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations.Allergy · 2026Article
- Tuberculosis and Post-Tuberculosis Lung Changes Are Associated with Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease: A Population-Based Retrospective Cohort Study.Journal of personalized medicine · 2026Article
- Economic Burden of Uncontrolled COPD Under Triple Therapy: A Population-Based Study.International journal of chronic obstructive pulmonary disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COPD is often managed with triple therapy (long-acting β Methods: This retrospective study included patients >40 years old, treated with triple therapy for ≥90 consecutive days in 2015, from the French National Health Data System. Patients were followed for up to 5 years. COPD patients were classified as uncontrolled (one or more severe, or two moderate exacerbations within 12 months before inclusion) or controlled. A random sample from the general population was included. Propensity score matching (1:2 for uncontrolled Results: Of 186 963 COPD patients on triple therapy, 21.3% (n=39 847) had uncontrolled COPD. Uncontrolled patients had a shorter overall survival and higher mortality risk compared with controlled patients (hazard ratio (HR) 1.21, 95% CI 1.18-1.23) and the general population (HR 2.51, 95% CI 2.45-2.57). Median time to first exacerbation was 0.39 years for uncontrolled Discussion: This study demonstrates the high clinical burden of uncontrolled COPD, defined by persistent exacerbations and characterised by reduced survival and frequent exacerbations despite triple therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.